Agent for ameliorating and/or preventing sickle cell disease
AssigneesThe University of Tokyo, Neopharma Japan Co., Ltd.
InventorsKenzaburo Tani, Yasushi Soda, Jiyuan Liao, Shohei Miyamoto, Satofumi Kawata, Motoyasu Tomioka, Ken Kodama
Life of this patent
Estimating the term…
Abstract
An agent for ameliorating and/or preventing sickle cell disease, includes 5-aminolevulinic acid (ALA) or a derivative thereof or a salt thereof. The agent is useful for amelioration and/or prevention of sickle cell disease. The agent may include one or more kinds of metal-including compounds. The metal in the metal-including compound can be any of several different metals, including iron, magnesium, zinc, nickel, vanadium, copper, chromium, molybdenum, or cobalt.
Claims15
A method for ameliorating sickle cell disease, comprising:
- administering an agent to a subject having hemoglobin S or βS mutation on HBB gene or showing a symptom of sickle cell disease in an amount effective for ameliorating the symptoms of sickle cell disease or effective to suppress onset of a symptom of sickle cell disease, the agent comprising a compound represented by Formula (I) below or a salt thereof:
- wherein:
- R1 represents a hydrogen atom or an acyl group;
- and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group.
A method for ameliorating sickle cell disease, comprising:
- administering an agent to a subject having sickle cell disease in an amount effective for ameliorating the symptoms of sickle cell disease or effective to suppress onset of a symptom of said sickle cell disease, the agent comprising a compound represented by Formula (I) below or a salt thereof:
- wherein:
- R1 represents a hydrogen atom or an acyl group;
- and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group.
Dependencies are inferred from the claim text.